Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 13/20 | 0.56 |
| ▸ | LIPG | Q9Y5X9 | 13/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14302548 | 0.95 | LPL (0.61) | LPLLIPGCYP2D6CYP3A4DGAT1 | |
| SCHEMBL18727880 | 0.92 | LPL (0.62) | LPLLIPGDGAT1CA1CA2 | |
| SCHEMBL25527190 | 0.91 | LPL (0.63) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL15037360 | 0.91 | LPL (0.63) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL22770755 | 0.89 | LPL (0.52) | LPLLIPGCYP2D6CYP3A4DGAT1 | |
| SCHEMBL14167807 | 0.89 | LPL (0.57) | LPLLIPGDGAT1CA1CA2 | |
| SCHEMBL21558596 | 0.88 | LPL (0.54) | LPLLIPGCYP3A4DGAT1CA1 | |
| SCHEMBL21311012 | 0.88 | LPL (0.54) | LPLLIPGDGAT1CA1CA2 | |
| SCHEMBL25405585 | 0.87 | LPL (0.53) | LPLLIPGDGAT1CA1CA2 | |
| SCHEMBL430495 | 0.87 | LPL (0.53) | LPLLIPGDGAT1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150158844-A1 | AROMATIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158844-A1 | AROMATIC HETEROCYCLIC COMPOUND | GPR119, NR0B1, BET1 | LPL 647/4885LIPG 1953/4885CYP2D6 1760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.